Behavioral Effects of Acute Systemic Low-Dose Clozapine in Wild-Type Rats: Implications for the Use of DREADDs in Behavioral Neuroscience

Frontiers in Behavioral Neuroscience
Ann-Kathrin IlgFlorian Bähner

Abstract

Designer receptors exclusively activated by designer drugs (DREADDs) are popular tools used to manipulate the activity of defined groups of neurons. Recent work has shown that DREADD effects in the brain are most likely not mediated by the proposed ligand clozapine-N-oxide (CNO) but its metabolite clozapine (CLOZ). However, it is not known whether low doses of CLOZ required to activate DREADDs already have DREADD-independent effects on behavior as described for higher CLOZ doses used in previous preclinical studies. To close this gap, we compared effects of acute systemic (i.p.) CLOZ treatment vs. vehicle (VEH) in a wide range of behavioral tests in male wild-type rats. We found that CLOZ doses as low as 0.05-0.1 mg/kg significantly affected locomotion, anxiety and cognitive flexibility but had no effect on working memory or social interaction. These results highlight the need for careful controls in future chemogenetic experiments and show that previous results in studies lacking CNO/CLOZ controls may require critical re-evaluation.

References

Oct 22, 1985·European Journal of Pharmacology·A M Snoddy, R E Tessel
Feb 1, 1973·Animal Behaviour·P A Russell, D I Williams
Apr 1, 1995·Pharmacology, Biochemistry, and Behavior·C A CastroM R Landauer
Jan 1, 1993·Journal of Neural Transmission. General Section·W Hauber
Sep 1, 1993·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·R J BaldessariniB M Cohen
Nov 12, 1996·Proceedings of the National Academy of Sciences of the United States of America·I InoueT Watanabe
May 1, 1997·Neuroscience and Biobehavioral Reviews·L J VanderschurenJ M Van Ree
May 1, 1997·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·S RuotsalainenP Riekkinen
May 7, 1998·European Journal of Pharmacology·K Krebs-ThomsonM A Geyer
Mar 18, 1999·Pharmacology, Biochemistry, and Behavior·J SetemA P Cruz
Aug 26, 1999·Neuropharmacology·N M Barnes, T Sharp
Jan 31, 2002·Progress in Neuro-psychopharmacology & Biological Psychiatry·Juan M ManzanequeJose F Navarro
Dec 14, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Sridhar NatesanShitij Kapur
Mar 16, 2007·Proceedings of the National Academy of Sciences of the United States of America·Blaine N ArmbrusterBryan L Roth
Apr 12, 2007·Behavioural Pharmacology·Kuchibhotla Vijaya KumarGautam Palit
Dec 27, 2008·Behavioural Brain Research·Stan B FlorescoTakeshi Enomoto
Jan 26, 2010·European Journal of Pharmacology·Akiko OkadaChiaki Kamei
Jan 15, 2011·Behavioural Brain Research·Phillip M BakerMichael E Ragozzino
Aug 9, 2012·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Caitlin E McOmishJay A Gingrich
Apr 11, 2013·Neuroscience Letters·Vera MarkvartovaFrantisek Vozeh
Apr 20, 2013·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·K R SerafimR Mattioli
Feb 20, 2016·Neuron·Bryan L Roth
Feb 26, 2016·Behavioral Neuroscience·Kyle S SmithStephen V Mahler
Nov 1, 2016·Alcohol and Alcoholism : International Journal of the Medical Council on Alcoholism·Dennis D RasmussenJanice C Froehlich
Feb 6, 2017·Science·Flavio DonatoEdvard I Moser
Apr 14, 2017·Psychopharmacology·M SzlachtaA Faron-Górecka
Aug 5, 2017·Science·Juan L GomezMichael Michaelides
Jan 6, 2018·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Stephen V Mahler, Gary Aston-Jones

❮ Previous
Next ❯

Citations

Aug 23, 2020·Brain Sciences·Lauren C Smith, Adam Kimbrough
Mar 21, 2020·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Nicholas A Upright, Mark G Baxter
Apr 9, 2020·Scientific Reports·Jongwook ChoHyoung-Ihl Kim
Jul 10, 2020·Brain Structure & Function·Laura DurieuxLucas Lecourtier
Mar 24, 2020·Molecular Psychiatry·Pramod C NairTarun Bastiampillai
Oct 29, 2020·Journal of the Experimental Analysis of Behavior·Paul L Soto
Nov 23, 2020·Brain, Behavior, and Immunity·Min-Hee YiLong-Jun Wu
May 21, 2021·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Eden M AndersonMatthew C Hearing
Nov 3, 2021·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Agata Casado-SainzMikael Palner
Dec 4, 2021·Molecular Therapy : the Journal of the American Society of Gene Therapy·Jingwei SongMichael Michaelides

❮ Previous
Next ❯

Software Mentioned

MedStat
Matlab
CLOZ
Excel
MedPC
Graphpad Prism
IV

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here